Esomeprazole Magnesium Capsule, Delayed Release Pellets
FDA Label NDC 62175-820

54 label sections · Submitted to the FDA by Lannett Company, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Lannett Company, Inc. for the product Esomeprazole Magnesium (NDC 62175-820). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 healing of erosive esophagitis (ee), 1.2 maintenance of healing of ee, 1.3 treatment of symptomatic gerd, 1.4 risk reduction of nonsteroidal anti-inflammatory drugs (nsaid)-associated gastric ulcer, 1.5 helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, 1.6 pathological hypersecretory conditions including zollinger-ellison syndrome, 2.1 recommended dosage in adults by indication, 2.2 recommended dosage in pediatric patients by indication, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.